European Biotech Acquisition Probability of Future Stock Price Finishing Over 11.19
| EBACDelisted Stock | USD 11.19 0.10 0.90% |
European |
European Biotech Target Price Odds to finish over 11.19
The tendency of European Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 11.19 | 90 days | 11.19 | near 1 |
Based on a normal probability distribution, the odds of European Biotech to move above the current price in 90 days from now is near 1 (This European Biotech Acquisition probability density function shows the probability of European Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days European Biotech Acquisition has a beta of -0.0381 suggesting as returns on the benchmark increase, returns on holding European Biotech are expected to decrease at a much lower rate. During a bear market, however, European Biotech Acquisition is likely to outperform the market. Additionally European Biotech Acquisition has an alpha of 0.1989, implying that it can generate a 0.2 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta). European Biotech Price Density |
| Price |
Predictive Modules for European Biotech
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as European Biotech Acq. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of European Biotech's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
European Biotech Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. European Biotech is not an exception. The market had few large corrections towards the European Biotech's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold European Biotech Acquisition, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of European Biotech within the framework of very fundamental risk indicators.α | Alpha over NYSE Composite | 0.20 | |
β | Beta against NYSE Composite | -0.04 | |
σ | Overall volatility | 0.26 | |
Ir | Information ratio | 0.04 |
European Biotech Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of European Biotech for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for European Biotech Acq can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| European Biotech Acq is not yet fully synchronised with the market data | |
| European Biotech Acq has a very high chance of going through financial distress in the upcoming years | |
| European Biotech Acquisition currently holds about 308.1 K in cash with (514.79 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02. | |
| Roughly 72.0% of the company shares are held by institutions such as insurance companies |
European Biotech Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of European Stock often depends not only on the future outlook of the current and potential European Biotech's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. European Biotech's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 12.8 M | |
| Cash And Short Term Investments | 308.5 K |
European Biotech Technical Analysis
European Biotech's future price can be derived by breaking down and analyzing its technical indicators over time. European Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of European Biotech Acquisition. In general, you should focus on analyzing European Stock price patterns and their correlations with different microeconomic environments and drivers.
European Biotech Predictive Forecast Models
European Biotech's time-series forecasting models is one of many European Biotech's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary European Biotech's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about European Biotech Acq
Checking the ongoing alerts about European Biotech for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for European Biotech Acq help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| European Biotech Acq is not yet fully synchronised with the market data | |
| European Biotech Acq has a very high chance of going through financial distress in the upcoming years | |
| European Biotech Acquisition currently holds about 308.1 K in cash with (514.79 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02. | |
| Roughly 72.0% of the company shares are held by institutions such as insurance companies |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the European Biotech Acq information on this page should be used as a complementary analysis to other European Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Other Consideration for investing in European Stock
If you are still planning to invest in European Biotech Acq check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the European Biotech's history and understand the potential risks before investing.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |